NCT02131415View on ClinicalTrials.gov

Real Life Assessment of Abilify Maintena

TerminatedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 15, 2017

Study Completion Date

February 15, 2017

Conditions
Schizophrenia
Trial Locations (17)

T2N 4Z6

CA012, Calgary

V2A 4M4

CA008, Penticton

V5Z 1M9

CA017, Vancouver

B3H 2E2

CA006, Halifax

K6V 5W7

CA011, Brockville

N7L 1C1

CA001, Chatham

K7L 4X3

CA014, Kingston

N2H 4A2

CA004, Kitchener

N6A 5W9

CA013, London

L5M 4N4

CA016, Mississauga

K1H 8L6

CA010, Ottawa

N9C 3Z4

CA002, Windsor

H1N 3M5

CA009, Montreal

H3A 1A1

CA003, Montreal

H4H 1R3

CA015, Montreal

G1J 2G3

CA005, Québec

G5R 2A4

CA019, Rivière-du-Loup

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Lundbeck Canada Inc.

INDUSTRY

NCT02131415 - Real Life Assessment of Abilify Maintena | Biotech Hunter | Biotech Hunter